Sessioni Poster
Pharmacogenetics and personalized medicine
Mercoledì 28 Ottobre 2015 / 19.00-20.00
5 | A case of QT prolongation during therapy with tamoxifen and trastuzumab: pharmacogenetic analysis to clarify the occurred event Antoniazzi S., Falvella FS., Massari F., Cheli S., Clementi E., Tomirotti M., Gambini D. |
46 | UGT1A1 and PPARA as genetic predictors of liver abnormalities in HIV infected patients on atazanavir treatment Cheli S., Riva A., Ricci E., Resnati C., Gervasoni C., Galli M., Clementi E., Falvella FS. |
205 | rs489693 melanocortin receptor-4 gene polymorphism is associated with the progression-free survival of glioblastoma patients treated with concomitant radio-chemotherapy Pasqualetti F., Orlandi P., Giuliani D., Cantarella M., Menghini V., Sechi A., Di Desidero T., Fioravanti A., Simeon V., Fabrini MG., Di Stefano AL., Sanson M., Danesi R., Guarini S., Bocci G. |
217 | The abacavir pharmacogenetic: screening of HLA-B*57.01 allele for preventing the hypersensitivity reaction Manzo V., Charlier B., Conti V., Izzo V., Corbi G., Russomanno G., Malangone P., Boffa N., Senatore C., Mazzeo M., Filippelli A. |
232 | Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. Perrone G ., Tassi R., Brugia M., Simi L., Petreni P., Mori E., Landini I ., Mazzei T., Pazzagli M ., Mini E., Nobili S. |
244 | Potential role of long noncoding RNA GAS5 in rapamycin-induced reversion of glucocorticoid resistance Lucafò M., Bravin V., Tommasini A., Di Silvestre A., Martelossi S., Ventura A., Decorti G., De Iudicibus S. |
252 | miRNA regulation during glucocorticoid treatment in children with inflammatory bowel disease De Iudicibus S., Lucafò M., Vitulo N., Zimbello R., Forcato C., Martelossi S., Di Silvestre A., Valle G., Ventura A., Decorti G. |
271 | Effect of renal transporter genetic polymorphisms on linezolid pharmacokinetic Allegra S., Cusato J., Baietto L., Fatiguso G., Ariaudo A., Corcione S., Di Perri G., De rOSA FG., D'Avolio A. |
272 | Identification of cellular models to study the role of the long noncoding RNA GAS5 as modulator of glucocorticoid response Di Silvestre A., Lucafò M., De Iudicibus S., Bravin V., Avian A., Romano M., Decorti G. |
274 | Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir Cusato J., De Nicolo' A., Boglione L., Cardellino CS., Allegra S., Bonifacio G., Cariti G., Di Perri G., D'Avolio A. |
296 | Migraine and its chronicization to medication overuse headache: a pharmacoepidemiologic pharmacogenetic approach Cargnin S., Terrazzino S., Da Cas R., Viana M., Sances G., Bianchi M., Ghiotto N., Tassorelli C., Nappi G., Canonico PL., Traversa G., Genazzani AA. |
333 | Clinical validity and utility of DPYD polymorphisms: the present and the future of pharmacogenetic tests Giodini L., Buonadonna A., Berretta M., De Paoli A., Scalone S., Miolo G., Mini E., Nobili S., Lonardi S., Pella N., Montico M., Roncato R., Dreussi E., Gagno S., Posocco B., Cecchin E., Toffoli G. |
341 | miRNA-related SNPs as new predictive biomarkers of response to neo-adjuvant treatment in rectal cancer patients? An explorative analysis Dreussi E., Polesel J., De Paoli A., Agostini M., Pucciarelli S., De Marchi F., Giodini L., Zanusso C., Gagno S., Roncato R., Toffoli G., Cecchin E. |
359 | Genetic polymorphisms as a stratification factor that contributes to identify patients at high risk of developing Anthracycline-induced cardiomyopathy Galli D., Fragni M., Ambrosiani L., Triggiani M., Cesana BM., Bonetti G., Cappellini S., Amoroso V., Simoncini EL., Berruti A., Spano P., Memo M., Nodari S., Sigala S. |
93 | Altered antioxidant enzymatic and non enzymatic status in seminal plasma of men with different reproductive problems Cerretani D., Micheli L., Collodel G., Menchiari A., Moltoni L., Moretti M., Fiaschi AI., Giorgi G. |
737 | Detection Of IVS14+1G>A in Dihydropyrimidine Dehydrogenase Gene And 5-Fluorouracil Chemotherapy In Patients With Solid Malignancies Vietri MT., Molinari AM., Capuano A., Caliendo G., Cenname A., Bernardi FF., Marabese I., Cioffi M., Rossi F. |
78 | KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA Del Re M., Tiseo M., D'Incecco A., Camerini A., Petrini I., Lucchesi M., Inno A., Spada D., Bordi P., Vasile E., Citi V., Malpeli G., Testa E., Gori S., Falcone A., Amoroso D., Chella A., Cappuzzo F., Ardizzoni A., Scarpa A., Danesi R. |
80 | Detection of secondary mutations associated with drug resistance in circulating tumor DNA of patients with advanced ALK+ NSCLC Belcari F., Bordi P., Del Re M., Citi V., Palombi M., Pinto C., Tiseo M., Danesi R. |
83 | Automation of a throughput system for the diagnosis and the genotyping of Hepatitis C Virus Zancan I., Renesto A., Paladin D., Giusti P. |
165 | Oxidative stress parameters in serum of Hashimoto's thyroiditis patients Vicchio TM., Certo R., Caccamo D., Certo G., Speciale A., Saija A., Gangemi S., Ruggeri RM., Cristani M., Centorrino F. |
194 | Development and validation of a One-Step RT-Real Time PCR kit for detection and quantification of BCR-ABL p210 Gonzalez P., Costanzi G., Paladin D., Giusti P. |
200 | The pharmacogenetics of tyrosine-kinase inhibitors in chronic myeloid leukemia: is there enough room for epigenetics? Polillo M., Galimberti S., Crea F., Hsuan Liu H., Clermont PL., Guerrini F., Ciabatti E., Ricci F., Barate' C., Fontanelli G., Barsotti S., Morganti R., Wang Y., Petrini M., Helgason CD., Danesi R., Di Paolo A. |
294 | Tamoxifen tailored treatment in breast cancer: splicing variants and pharmacogenetic profiles of ESR1 gene as new promising biomarkers Bertolaso L., Pezzolo E., Pasini F., Gusella M. |
332 | Pharmacokinetic analysis of weekly paclitaxel from patients enrolled in a genotype-driven phase I study: new horizon for conventional chemotherapeutic drugs Posocco B., Marangon E., Giodini L., Scalone S., Sorio R., Toffoli G. |
459 | Epicardial fat thickness is a marker of preclinical cardiovascular disease in the general population Baragetti A., Pisano G., Garlaschelli K., Grigore L., Fracanzani AL., Fargion S., Norata GD., Catapano AL. |
596 | Set-up experiments for microRNAs characterization in plasma and circulating tumor cells derived from patients with cutaneous melanoma Polini B., Carpi S., Pardini B., Naccarati A., Romanini A., Fogli S., Nieri P. |
645 | microRNAs as biomarkers of oxidant/antioxidant status Balestra B., Lupo G., Paolini A., Pastoris O., Capelli E. |
670 | Sex differences in metabolomic profile used for newborn screening Ruoppolo M., Scolamiero E., Caterino M., Mirisola V., Franconi F., Campesi I. |
696 | The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 Nassini R., Massi D., Brusa D., Merelli B., Falcone C., Xue G., Carobbio A., Baroni G., Tamborini E., Cattaneo L., Audrito V., Deaglio S., Mandalà M. |